Unraveling the Mystery: Why Cancer Treatments Succeed in Monkeys but Fail in Humans
In a groundbreaking study, researchers have uncovered a fascinating discrepancy between how a key immune checkpoint, TIGIT, behaves in rhesus macaques and humans. This revelation has significant implications for the development of cancer therapies and raises important questions about our current approach to drug testing.
TIGIT, short for T cell immunoreceptor with Ig and ITIM domains, acts as a crucial brake on our immune system. It's found on specific immune cells, including T cells and natural killer (NK) cells, and prevents them from launching aggressive attacks. Unfortunately, cancer cells exploit this mechanism to evade immune destruction.
Cancer immunotherapy drugs aim to release this brake, allowing the immune system to fight tumors more effectively. However, despite promising results in animal models, multiple anti-TIGIT antibodies have failed in Phase III trials for solid tumors. This has left scientists scratching their heads, wondering what's going on.
The Rhesus Macaque Enigma
The new research reveals a fascinating difference between rhesus macaques and humans. When exposed to plasmin, a natural enzyme involved in blood clot breakdown, rhesus macaques shed TIGIT from the surfaces of their immune cells. Plasmin is highly active in nearly all solid cancers, suggesting a potential link to the immune system's response.
This shedding process creates a soluble form of TIGIT that can still bind to anti-TIGIT monoclonal antibodies, such as tiragolumab, an experimental cancer therapy. In macaques, this means the antibodies might be absorbed by the free-floating TIGIT, rather than blocking immune suppression on tumor-fighting cells. This could explain why some therapies have underperformed in late-stage trials.
Jogender Tushir-Singh, an associate professor and senior author of the study, emphasizes the implications: "Tests in macaques will not predict proper safety and dose estimation data for human clinical trials. It seems like TIGIT biology and mechanism are much more complex than expected."
A Single Amino Acid Makes All the Difference
The researchers delved deeper, examining TIGIT proteins from humans and monkeys. They discovered that a single amino acid difference at position 119 in the monkey protein makes TIGIT more susceptible to cleavage by plasmin. When plasmin was added to immune cells, only monkey cells shed TIGIT, confirming the species-specific nature of this phenomenon.
Implications for Cancer Drug Development
These findings suggest that testing TIGIT-targeted therapies in macaques may provide misleading data on safety and efficacy. It highlights the need for more accurate models that better reflect human biology when developing immunotherapies.
Tushir-Singh concludes, "The study underscores the importance of considering species differences in preclinical studies, especially for immune checkpoint-targeting drugs."
This research not only sheds light on the complexities of cancer treatment development but also opens up a fascinating discussion on the limitations of animal models in medical research. It's a reminder that while animal studies are crucial, they may not always translate directly to human biology.
What are your thoughts on this? Do you think we should reevaluate our approach to drug testing, or are there other factors at play? Let's discuss in the comments and explore these intriguing possibilities further!
